Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. (Q40149920)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Reinhard Vonthein

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Sascha Venturelli

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Sorin Armeanu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Anita Pathil

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Chih-Jen Hsieh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Manfred Wehrmann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Michael Gregor

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Ulrich M Lauer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Michael Bitzer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

language of work or name

English

0 references

publication date

1 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

number of pages

10

1 reference

inferred from page(s)

published in

Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

2132-2141

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17407132%20AND%20SRC:MED&resulttype=core&format=json

Aberrant Promoter Methylation Profiles of Tumor Suppressor Genes in Hepatocellular Carcinoma

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

CpG island methylation in gastroenterologic neoplasia: a maturing field.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Epigenetics in human disease and prospects for epigenetic therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Apoptotic speck protein-like, a highly homologous protein to apoptotic speck protein in the pyrin domain, is silenced by DNA methylation and induces apoptosis in human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

5-Azacytidine, DNA Methylation, and Differentiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

DNA methylation and cancer therapy: new developments and expectations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Rational development of histone deacetylase inhibitors as anticancer agents: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Making bad cells go good: the promise of epigenetic therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Anti-tumor mechanisms of valproate: a novel role for an old drug

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Cellular damage to human hepatocytes through repeated application of 5-aminolevulinic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

New colorimetric cytotoxicity assay for anticancer-drug screening

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Sendai virus infection induces apoptosis through activation of caspase-8 (FLICE) and caspase-3 (CPP32).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Caspase-8, death-receptor signaling, and hepatocarcinogenesis: the Fas and the furious

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

DNA methylation and chromatin - unraveling the tangled web.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Valproate induces replication-independent active DNA demethylation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22652

7 January 2021